Exelixis (EXEL) Rating Reiterated by Oppenheimer

Exelixis (NASDAQ:EXEL)‘s stock had its “hold” rating reiterated by analysts at Oppenheimer in a report released on Wednesday.

Several other research analysts have also issued reports on the stock. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Leerink Swann lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $34.00 to $28.00 in a research note on Friday, September 22nd. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 target price on the stock in a research note on Tuesday, January 2nd. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Wednesday, October 18th. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of Exelixis in a research note on Monday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $32.13.

Exelixis (NASDAQ:EXEL) opened at $27.86 on Wednesday. The stock has a market cap of $8,240.00, a price-to-earnings ratio of 56.86, a P/E/G ratio of 0.89 and a beta of 1.88. Exelixis has a 12 month low of $16.72 and a 12 month high of $32.50.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.18. The business had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. Exelixis’s revenue was up 145.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.04) earnings per share. equities analysts anticipate that Exelixis will post 0.49 EPS for the current fiscal year.

In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total transaction of $454,500.00. Following the transaction, the director now owns 64,829 shares in the company, valued at $1,964,318.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 5.10% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its holdings in Exelixis by 2.0% during the second quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock worth $1,077,530,000 after buying an additional 857,452 shares during the last quarter. Vanguard Group Inc. raised its holdings in Exelixis by 7.2% during the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock worth $626,635,000 after buying an additional 1,706,893 shares during the last quarter. Matrix Capital Management Company LP raised its holdings in Exelixis by 8.8% during the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after buying an additional 1,225,000 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Exelixis by 13.1% during the second quarter. Goldman Sachs Group Inc. now owns 7,059,232 shares of the biotechnology company’s stock worth $173,869,000 after buying an additional 818,782 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Exelixis by 6.5% in the third quarter. Jennison Associates LLC now owns 3,061,003 shares of the biotechnology company’s stock valued at $74,168,000 after purchasing an additional 187,654 shares during the last quarter. Hedge funds and other institutional investors own 80.84% of the company’s stock.

WARNING: “Exelixis (EXEL) Rating Reiterated by Oppenheimer” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2018/01/19/exelixis-exel-rating-reiterated-by-oppenheimer.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply